Glenmark gets warning letter from USFDA for lapses at Goa plant

Glenmark Pharmaceuticals has been pulled up by the US health regulator owing to manufacturing lapses including failure to establish required laboratory control mechanisms, at its Goa-based manufacturing plant. The USFDA, in a warning letter addressed to Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha, pointed out various lapses at the company's Bardez-based facility in Goa, which produces drug formulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jKFr3yY
via IFTTT